I-Tenofovir Alafenamide Hemifumarate TAF CAS 1392275-56-7 API Factory Anti-HIV High Quality
Ubonelelo ngezoRhwebo lwe-Tenofovir oluNxulumene naMaphakathi:
I-Tenofovir CAS: 147127-20-6
I-Tenofovir Disoproxil Fumarate CAS 202138-50-9
I-Tenofovir Alafenamide Hemifumarate CAS 1392275-56-7
I-Chloromethyl Isopropyl Carbonate CAS 35180-01-9
I-Diethyl (p-Toluenesulfonyloxymethyl)phosphonate CAS 31618-90-3
(R)-(+)-Propylene Carbonate CAS 16606-55-6
(R)-9-(2-Hydroxypropyl)adenine CAS 14047-28-0
I-Diethyl (Hydroxymethyl)phosphonate CAS 3084-40-0
Adenine CAS 73-24-5
Igama leMchiza | I-Tenofovir Alafenamide Hemifumarate |
Izithethantonye | TAF;GS-7340 Hemifumarate |
Inombolo yeCAS | 1392275-56-7 |
Inombolo yeCAT | RF-API91 |
Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram |
Ifomula yeemolekyuli | I-C25H33N6O9P |
Ubunzima beMolekyuli | 592.55 |
Ubushushu boGcino | Itywinwe kwindawo eyomileyo, ubushushu beGumbi |
Uphawu | Ruifu Chemical |
Into | Iinkcukacha |
Imbonakalo | Mhlophe ukuya Phantse iiCrystals eziMhlophe okanye umgubo weCrystalline |
Ukunyibilika | I-Soluble kwi-Dimethylformamide, kunye ne-Methanol;Inyibilika kancinane emanzini nakwi-THF;Inyibilika kancinane kwiAcetonitrile kwaye ayinyibiliki kwiDichloromethane kunye neToluene |
Isazisi A | I-IR yokufunxa i-spectra kufuneka ihambelane nereferensi |
Isazisi B | Ixesha lokugcinwa kwencopho enkulu yesisombululo sesampulu kwichromatogram yokuzimisela komxholo ihambelana naleyo yesisombululo sereferensi. |
Isazisi C | Ixesha lokugcinwa kwe-Fumaric Acid lencopho enkulu kwichromatogram yokuzimisela komxholo ihambelana nencopho yereferensi. |
Isiqulatho samanzi (nge-KF) | ≤1.0% |
Ukucaca kwesisombululo | Ngokwenene akukho zincinci ezibonakalayo kwi-2% (w / v) ye-Methanol Solution yokucacisa |
Intsalela yokunyibilika | |
Acetonitrile | ≤410ppm |
I-Ethanol | ≤5000ppm |
Dichloromethane | ≤600ppm |
Toluene | ≤890ppm |
Intsalela kwi-Ignition | ≤0.10% |
Iintsimbi ezinzima | ≤20ppm |
Izinto ezinxulumeneyo | |
PMPA | ≤1.0% |
PMPA Anhydride | ≤0.75% |
Phenyl PMPA eyodwa | ≤1.0% |
Nakuphi na Ukungcola Okungachazwanga | ≤0.15% |
Ukungcola ngokupheleleyo | ≤2.0% |
Isomer | ≤1.0% |
Umxholo weFumaric Acid | 9.0% ~ 13.0% (kwisiseko se-anhydrous) |
Imida yeMicrobial | |
Ubalo olupheleleyo lweAerobic Microbial | ≤1000CFU/g |
I-Yeasts iyonke kunye ne-Molds Bala | ≤100CFU/g |
Escherichia Coli | Ukungabikho |
Isivavanyi | 98.0% ~ 102.0% (kwisiseko se-anhydrous kunye ne-solvent-free basis) |
Umgangatho woVavanyo | Umgangatho woShishino |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.
I-Tenofovir Alafenamide Hemifumarate (TAF, GS-7340 hemifumarate), CAS 1392275-56-7, yi-nucleotide reverse transcriptase inhibitor (NRTIs) kunye neprodrug yenoveli yeTenofovir (TFV).Ngokuthintela i-reverse transcriptase, i-TAF ithintela i-HIV ekubeni iziphindaphinde kwaye inokwehlisa umthamo we-HIV emzimbeni.I-Tenofovir alafenamide liyeza, nto leyo ethetha ukuba lichiza elingasebenziyo.Emzimbeni, i-tenofovir alafenamide iguqulelwa ekubeni yi-Tenofovir diphosphate (TFV-DP).I-Tenofovir Alafenamide Fumarate yamkelwa ngoNovemba ka-2015 kunyango lwe-HIV-1.